SAN FRANCISCO and SEOUL, South Korea, Jan. 30, 2018 /PRNewswire/ -- Syapse, a leading precision medicine company, announced today it is expanding to Asia through new partnerships with Seoul National University Hospital (SNUH), the premier hospital in Korea, and Megazone, a cloud-specialized IT company.
Syapse and SNUH are launching a precision oncology program to improve cancer care in Korea, with the support of Megazone's innovative cloud services. SNUH, one of the largest health systems in South Korea, is the first health system outside the U.S. to use the Syapse platform. Through the new partnership, physicians at SNU Cancer Hospital's 28 centers will use Syapse's point-of-care software platform to deliver more effective, personalized cancer therapies. Syapse's software enables oncologists to implement large-scale precision medicine by integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions.
"We believe all cancer patients should have access to the best precision care, regardless of location, and I'm excited that Syapse is expanding internationally and partnering with Seoul National University Hospital and Megazone," said Ken Tarkoff, CEO of Syapse. "SNUH has long been on the cutting edge in both cancer care and technology, and I'm thrilled to be partnering with them to help bring precision medicine to patients in South Korea."
SNU Cancer Hospital, opened in March 2011 and based in Seoul, is dedicated to providing the best medical services to cancer patients. The hospital includes 16 Cancer Specialty Centers, 10 Multidisciplinary Cancer Treatment Centers, and a Cancer Clinical Trials Center.
"Syapse give us a powerful platform to make effective cancer treatment decisions by using molecular analysis technology," said Kyung Hwan Kim, M.D., Thoracic and Cardiovascular Surgery, Chief Information Officer of SNUH. "And through our precision medicine platform, we hope Seoul National University Hospital will provide a new standard for the evidence-based precision treatment of cancer."
With precision medicine, physicians at SNUH will be able to deliver precision care based on a patient's clinical and genomic profile, an approach that has been shown to improve outcomes, lower costs, and increase efficiency. SNUH will join the Syapse network of leading providers, such as Providence St. Joseph Health and Aurora Health Care in the U.S., that benefit from real-world insights into which treatments are most effective.
Syapse's expansion into Asia will be accelerated through its multi-year partnership with Megazone. This partnership will bring precision medicine to health systems and patients throughout the Asia-Pacific region, initially focusing on Korea, Japan, and Vietnam.
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health—manage one million active cancer cases at nearly 300 hospitals in 25 states. Headquartered in San Francisco, Syapse is backed by investors including Social Capital, Safeguard Scientifics (NYSE: SFE), Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures.
About Seoul National University Hospital
Seoul National University Hospital has been looking after public health over the past 100 years and leading the development of medicine in Korea. It was established in 1885 as Korea's first national hospital under the name Kwang Hye Won. Later, it became the affiliate hospital for Seoul National University 's College of Medicine and College of Dentistry before being recognized as a special corporate body under the name of Seoul National University Hospital.
Today the hospital is comprised of the Main Hospital, the Children's Hospital, the Cancer Hospital, the Dental Hospital, and the Clinical Research Institute. With over 1,700 hospital beds, approximately 2,000 inpatients and 8,000 outpatients are treated each day by 533 medical professors and 5,800 staff.
With the arrival of the 21st century, Seoul National University Hospital is striving to develop into a world-class hospital, safeguarding the health of humankind. The hospital's vision for the 21st century is based on patient-oriented care, respect for humankind, the creation of knowledge and public service.
MEGAZONE is a cloud-specialized IT company aiming to become a "cloud innovator," with approximately 480 employees focused on the cloud as the next-gen business. In 2015, MEGAZONE became the first Premier Consulting Partner of Amazon Web Services in Korea, among only 55 others worldwide. In 2016 and 2017, MEGAZONE was awarded "AWS Partner of the Year" for two consecutive years and was also awarded "AWS Partner of the Year APAC" in 2017.
View original content with multimedia:http://www.prnewswire.com/news-releases/syapse-expands-precision-medicine-to-asia-through-partnerships-with-seoul-national-university-hospital-and-megazone-300590117.html